All In Biotech

Drug Trial Radar · NCT06079359

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 Versus Placebo Administered Subcutaneously in Pediatric (2 to < 12 Years of Age) Participants With Hypophosphatasia Who Have Not Received Previous Treatment With Asfotase Alfa

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

30

Actual

Start

May 14, 2024

Primary completion

Jan 6, 2026

Study completion Aug 24, 2028

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the efficacy of ALXN1850 versus placebo on radiographic outcomes in pediatric participants with HPP who have not previously been treated with asfotase alfa.

Conditions

  • Hypophosphatasia

Interventions

  • ALXN1850Drug

    Participants will receive a ALXN1850 via subcutaneous (SC) injection.

  • PlaceboDrug

    Participants will receive placebo via SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Global Impression of Change (RGI-C) Score at the end of the Randomized Evaluation Period (Day 169)Time frame: Day 169

Locations

32 sites in 16 countries. Site status is shown where the registry gives one.

  • Research Site

    Baltimore, Maryland

  • Research Site

    Kansas City, Missouri

  • Research Site

    Durham, North Carolina

  • Research Site

    Nedlands, Australia

  • Research Site

    Parkville, Australia

  • Research Site

    Brussels, Belgium

  • Research Site

    Brasília, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Recife, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Winnepeg, Manitoba, Canada

  • Research Site

    Beijing, China

  • Research Site

    Guangzhou, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenzhen, China

  • Research Site

    Helsinki, Finland

  • Research Site

    Ashkelon, Israel

  • Research Site

    Chihuahua City, Mexico

  • Research Site

    Lodz, Poland

  • Research Site

    Bucharest, Romania

  • Research Site

    Madrid, Spain

  • Research Site

    Vitoria-Gasteiz, Spain

  • Research Site

    Stockholm, Sweden

  • Research Site

    Taipei, Taiwan

  • Research Site

    Ankara, Turkey (Türkiye)

  • Research Site

    Bursa, Turkey (Türkiye)

  • Research Site

    Erzurum, Turkey (Türkiye)

  • Research Site

    Istanbul, Turkey (Türkiye)

  • Research Site

    Birmingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.